Company news

Immuron Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Immuron Travelers Diarrhea Market Update

October 12, 2020

Appendix 4E and 2020 Financial Report

August 31, 2020

Immuron Announces US$20.0 Million Registered Direct Offering

July 21, 2020

Immuron Reports Neutralizing activity Against SARS-CoV-2

July 21, 2020

US DoD Receives FDA Guidance on clinical development plans

July 20, 2020

IMC & CSIRO to produce oral therapeutic for DoD evaluation

June 19, 2020

Response to ASX Price Query

June 10, 2020

Immuron Global Sales Up 60%

April 20, 2020

Resignation of Managing Director and cuts amid Covid19

March 24, 2020

North American Travelan sales up 98% to Dec 2019

January 27, 2020

Immuron Plans IMM-124E Trial to Prevent Travelers Diarrhea

November 20, 2019

Immuron Receives AUD $0.53M R&D Tax Concession Refund

November 3, 2019

Immuron North American Q1 Sales Up 111% YoY

October 13, 2019

US Defense funds AU$5.5M for Immuron New Gastro Weapon

October 1, 2019

US Defense Reports Immuron Travelan Targets Cholera

September 3, 2019

Appendix 4E & Annual Report to shareholders

August 30, 2019

Immuron Reports Results in SAH Clinical Trial

August 7, 2019

Underwritten Public Offer

July 17, 2019

Immuron Prices Underwritten Public Offering of ADSs

July 17, 2019

Proposed Public Offer of IMRN ADSs

July 16, 2019

Immuron North American revenue surges by 52% in FY19

July 16, 2019

US DoD Reports Results from Travelan Shigellosis Study

June 12, 2019

Preliminary Prospectus Supplement filed with SEC

May 24, 2019

Trading halt

May 23, 2019

Immuron Appoints CEO Dr. Gary S. Jacob to Board of Directors

April 16, 2019

Immuron sales surge by 66% in the Third Quarter of FY19

April 14, 2019

Immuron Aims to Secure FDA Approval for IMM-124E

April 10, 2019

Company Update on CDI Clinical Trial and New Strategic Focus

March 18, 2019

Travelan FY19 Update and Expansion into North America

January 28, 2019

Form F-3

January 14, 2019

Immuron Receives $1.19M R&D Tax Concession Refund

January 2, 2019

IMC Appoints Experienced US Based Biotech Executive as CEO

November 18, 2018

NASH clinical trial presentation & continued revenue growth

November 9, 2018

US DoD Report Travelan Protects Against Shigella in Primates

September 4, 2018

Immuron Reports Record Revenue

July 25, 2018

US Department of Defense Research Collaboration Moves Ahead

July 15, 2018

European Patent Gramted for Nash Treatment

July 11, 2018

Immuron Announces Board Appointment

June 26, 2018

IMC Preclinical Study Reports Reduction in Colitis Symptoms

May 8, 2018

Travelan Sales Continue to Soar in Third Quarter of FY2018

April 23, 2018

Immuron Announces A$5.1M Private Placement to U.S. Fund

March 13, 2018

Immuron Reports Positive Results in NASH Clinical Trial

March 7, 2018

Correction to False and Misleading News Release

March 6, 2018

Appendix 4D - Half Year Financial Report - 31 Dec 2017

February 27, 2018

Travelan Revenue Grows Significantly in US and Australia

February 16, 2018

US Defence Depart Report-Travelan Targets Priority Pathogens

January 29, 2018

Immuron to Receive $2.16M R&D Tax Concession Cash Refund

January 22, 2018

Immuron Granted US Patent for NASH Treatment

November 13, 2017

Immuron Successfully Completes NASH Phase II Clinical Study

November 8, 2017

Travelan Experiences Strong Q1 FY2018 Sales Growth

November 7, 2017

← Newer news releases · Older news releases →

Decks

The 5 newest of 106 decks. Every deck is listed under its year.